These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 31502263

  • 1. Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.
    Witjes H, Khatri A, Diderichsen PM, Mandema J, Othman AA.
    Clin Pharmacol Ther; 2020 Feb; 107(2):435-442. PubMed ID: 31502263
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
    Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG.
    JAMA Dermatol; 2020 Jun 01; 156(6):649-658. PubMed ID: 32267471
    [Abstract] [Full Text] [Related]

  • 3. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C.
    Lancet; 2019 Aug 17; 394(10198):576-586. PubMed ID: 31280967
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.
    Lancet; 2018 Aug 25; 392(10148):650-661. PubMed ID: 30097359
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 25; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
    Ohtsuki M, Fujita H, Watanabe M, Suzaki K, Flack M, Huang X, Kitamura S, Valdes J, Igarashi A.
    J Dermatol; 2019 Aug 25; 46(8):686-694. PubMed ID: 31237727
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
    J Am Acad Dermatol; 2017 Mar 25; 76(3):405-417. PubMed ID: 28057360
    [Abstract] [Full Text] [Related]

  • 8. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
    Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN.
    Br J Dermatol; 2019 Jun 25; 180(6):1348-1351. PubMed ID: 30632140
    [Abstract] [Full Text] [Related]

  • 9. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis.
    Lebwohl M, Soliman AM, Yang H, Wang J, Freimark J, Puig L.
    J Dermatolog Treat; 2022 Jun 25; 33(4):2094-2101. PubMed ID: 33899655
    [Abstract] [Full Text] [Related]

  • 10. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
    Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA.
    Br J Dermatol; 2023 Oct 25; 189(5):540-552. PubMed ID: 37488811
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
    Suleiman AA, Khatri A, Oberoi RK, Othman AA.
    Clin Pharmacokinet; 2020 May 25; 59(5):575-589. PubMed ID: 31667790
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
    Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, Geng Z, Paul C.
    Br J Dermatol; 2021 Jan 25; 184(1):50-59. PubMed ID: 32594522
    [Abstract] [Full Text] [Related]

  • 16. A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.
    Nawas Z, Hatch M, Ramos E, Liu M, Tong Y, Peranteau A, Tyring S.
    Skin Therapy Lett; 2017 Mar 25; 22(2):8-10. PubMed ID: 28329405
    [Abstract] [Full Text] [Related]

  • 17. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.
    Blair HA.
    Drugs; 2020 Aug 25; 80(12):1235-1245. PubMed ID: 32632826
    [Abstract] [Full Text] [Related]

  • 18. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
    Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.
    JAMA Dermatol; 2020 Mar 01; 156(3):258-269. PubMed ID: 32022825
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
    Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB.
    Dermatol Ther (Heidelb); 2022 Feb 01; 12(2):561-575. PubMed ID: 35050485
    [Abstract] [Full Text] [Related]

  • 20. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.
    J Dermatol Sci; 2020 Jul 01; 99(1):53-61. PubMed ID: 32600737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.